期刊
CLINICA CHIMICA ACTA
卷 503, 期 -, 页码 203-209出版社
ELSEVIER
DOI: 10.1016/j.cca.2019.11.032
关键词
Lactate dehydrogenase C4; Breast cancer; Serum; Exosome; Diagnosis; Prognosis
资金
- National Natural Science Foundation of China [81802631]
- Fujian Provincial Health Technology Project [2016-ZQN-17]
- Joint Funds for the Innovation of Science and Technology, Fujian province [2017Y9073]
- Science and Technology Program of Fujian Province, China [2018Y2003]
Background: Lactate dehydrogenase C4 (LDH-C4) as a cancer/testis antigen (CTA) is abnormally expressed in some malignant tumors. However, the expression and clinical significance of LDH-C4 in breast cancer (BC) has not been characterized. Methods: We determined LDHC mRNA expression in serum and serum-derived exosomes of BC patients by quantitative RT-PCR. We also evaluated the protein expression of LDH-C4 in BC tissues using high-throughput tissue microarray analysis and immunohistochemistry. Results: Our results showed high mRNA expression level of LDHC in serum and serum-derived exosomes of BC patients. The LDHC level in serum and exosomes could distinguish BC cases from healthy individuals based on their AUCs of 0.9587 and 0.9464, respectively. Besides, the LDHC level in exosomes of BC patients associated with tumor size, and positively correlated with HER2 and Ki-67 expressions (all with P < 0.05). Serum and exosomal level of LDHC negatively correlated with medical treatment and positively with the recurrence of BC. Survival analysis showed that LDH-C4 expression negatively correlated with BC prognosis. Conclusion: Serum and exosomal LDHC may be an effective indicator for the diagnosis, efficacy evaluation, and monitoring the recurrence of BC. LDH-C4 may act as a biomarker that predicts BC prognosis.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据